
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/G8_feoEer8k/150629124501.htm